Imagine you’re in a field the size of Alaska. Now, imagine you’re tasked with finding one specific blade of grass in that field. Seems impossible, doesn’t it?
Enter Simoa, our single molecule array technology. Simoa is so sensitive that it allows scientists and researchers to see minute concentrations of biomarkers in blood and other bodily fluids at this equivalence.
Building on the success of our flagship Simoa HD-1 Analyzer, which is enabling researchers worldwide to see and measure critical biomarkers that have previously gone undetected, we’re thrilled to announce the launch of the new SR-X Ultra-Sensitive Biomarker Detection System, expanding our portfolio of technologies to now include a benchtop instrument.
The SR-X employs single molecule measurements to bring this same unprecedented detection power to researchers, but with a smaller instrument footprint that has been optimized for increased multiplexing capabilities – making it an easy-to-use and economical option for high sensitivity biomarker analysis.
The SR-X is part of a complete solution that includes a menu of more than 70 ultra-sensitive protein detection assays, as well as a newly introduced series of multiplex assays for critical biomarkers, including the first six-plex Simoa assay for quantitative measurement of inflammatory biomarkers in the blood. The SR-Plex also makes great strides in miRNA research, providing scientists with a PCR-free method for measuring nucleic acids. Recently, this technique was validated in a PLOS ONE study on liver toxicity, which showed Simoa to be faster and 500x more sensitive than traditional detection methods.
To date, our Simoa technology has been used in more than 145 studies published in peer-reviewed journals, and this research spans a number of key therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. Through these studies, Simoa has shown the potential to detect biomarkers in the subclinical state, which is extremely valuable for the monitoring of neurodegeneration in diseases such as Alzheimer’s and multiple sclerosis.
With our new SR-X instrument, we’re particularly excited with the device’s potential to lead to advances in the application of circulating biomarkers, especially for cancer detection and treatment. While there have been a number of recent innovations in the field of genomic and proteomic technologies, we’ve yet to see adequate advancement with regard to the development of tests for immunological biomarkers, something that leaves us with significant room for improvement. But now, for the first time ever, the SR-X's multiplexing capabilities and digital sensitivity capabilities provide the ability for researchers to measure economically circulating clinically relevant concentrations of immunological mediators, exosomes and miRNA in a single benchtop instrument.
Our SR-X was met with universally warm reception when it was first unveiled at the Next Generation Dx Summit in Washington, D.C. last month and as part of an early-access program, Myriad RBM, Inc., the world’s leading multiplexed immunoassay testing laboratory, will begin using the device starting in the fourth quarter of 2017. Myriad RBM has previously worked with our Simoa HD-1 Analyzer, but now with a benchtop instrument that also offers multiplexing capabilities, Myriad plans to optimize their in-house laboratory robotics, as well as liquid handlers, to help advance research and also reduce their overall expenditures.
Following this early-access program, we anticipate that the SR-X will be fully available in the first quarter of 2018 for widespread adoption. The SR-X is for research use only and not for use in diagnostic procedures.
Through continued innovation, we’ll continue to make strides in the field of precision medicine, and it’s our hope that the new SR-X will help advance our mission of changing the way in which healthcare is provided by giving researchers the ability to closely examine the continuum from health to disease.